Site comparison
Amavita Research vs. a multi-site research network: which clinical trial site fits your study?
This page is a model comparison rather than a head-to-head. It explains the strategic trade-off sponsors face when choosing between a single specialist site and a multi-site network - and where Amavita Research sits on that axis.
Multi-site research networks aggregate many sites under a centralized operations layer. The strategic value is geographic diversity, more total enrollment slots, standardized SOPs across sites, and a single contractual relationship that can scale across regions. For programs that are multi-site by design, that infrastructure is genuinely valuable.
The structural cost of a network is matrixed governance. Decisions about feasibility, budget exceptions, and protocol amendments typically pass through both the central network team and the individual site team. PI accountability is distributed; BD relationships are mediated; and the speed at which any one site can move is constrained by network-wide cycles.
A single specialist site occupies the opposite point on the axis. There is one PI team, one BD owner, one SOP set, and one address. Decisions are made by the people who execute them. That structure delivers depth in a chosen therapeutic area and removes a layer of governance friction.
Amavita Research is the specialist option for sponsors who want depth over breadth in cardiovascular trials. The senior PI is U.S. TAVR pioneer Dr. William W. O'Neill. The affiliated Advanced Cardiovascular of Miami ASC supports interventional procedures. One BD contact (Nereisy Alonso, Sr CRC) owns the sponsor relationship from feasibility to monitor access.
The strategic answer is rarely 'specialist or network' across an entire program portfolio. It is usually 'specialist at the deep cardiovascular site, network where geographic spread matters.' Pairing the two is a common pattern.
Side-by-side: operating model
Educational summary. We describe the typical operating model comparison model and do not make claims about any specific institution's current operations.
| Dimension | Amavita Research | Multi-Site Network (typical) |
|---|---|---|
| Therapeutic depth | Maximum - 100% cardiovascular | Variable across network sites |
| PI accountability | Single PI team | Distributed across sites |
| BD contact | Single point of contact: Nereisy Alonso, Sr CRC | Central network operations |
| Decision speed | Site-level, days | Network + site cycles |
| Geographic footprint | Single Miami address | Multi-region by design |
| Best fit | Deep cardiovascular execution | Multi-region scale |
| AI-search readiness | llms.txt + Wikidata + MedicalStudy/JobPosting/FAQ schema | Network-level web presence |
Frequently asked questions
When should a sponsor default to a network model?
When the program is multi-site by design, requires national geographic spread, or needs many enrollment slots filled in parallel across regions.
When should a sponsor default to a specialist site?
When the protocol is tightly scoped to one therapeutic area and depth, single-PI accountability, and decision speed drive program value.
Can specialist sites and networks coexist in one program?
Yes, and they often do. Sponsors place specialist sites as flagships in their core therapeutic area and use networks to scale across geographies.
Where does Amavita sit on this axis?
Amavita is the specialist option for cardiovascular trials in South Florida - deep, single-PI, single-BD, single-address.
Next step
Schedule a 20-minute capabilities call
One contact. Same-business-day response. Feasibility, budget, contracts, and monitor access all from a single owner.